Cancel anytime
Mednax Inc (MD)MD
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/15/2024: MD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 2.94% | Upturn Advisory Performance 2 | Avg. Invested days: 31 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/15/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 2.94% | Avg. Invested days: 31 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/15/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD |
Price to earnings Ratio - | 1Y Target Price 15.92 |
Dividends yield (FY) - | Basic EPS (TTM) -2.34 |
Volume (30-day avg) 718040 | Beta 1.55 |
52 Weeks Range 6.62 - 16.41 | Updated Date 11/19/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 15.92 |
Dividends yield (FY) - | Basic EPS (TTM) -2.34 | Volume (30-day avg) 718040 | Beta 1.55 |
52 Weeks Range 6.62 - 16.41 | Updated Date 11/19/2024 |
Earnings Date
Report Date 2024-11-01 | When BeforeMarket |
Estimate 0.37 | Actual 0.44 |
Report Date 2024-11-01 | When BeforeMarket | Estimate 0.37 | Actual 0.44 |
Profitability
Profit Margin -12.65% | Operating Margin (TTM) 10.26% |
Management Effectiveness
Return on Assets (TTM) 4.67% | Return on Equity (TTM) -29.86% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE 9.43 |
Enterprise Value 1717914915 | Price to Sales(TTM) 0.63 |
Enterprise Value to Revenue 0.86 | Enterprise Value to EBITDA 69.27 |
Shares Outstanding 85880496 | Shares Floating 74984933 |
Percent Insiders 1.67 | Percent Institutions 106.33 |
Trailing PE - | Forward PE 9.43 | Enterprise Value 1717914915 | Price to Sales(TTM) 0.63 |
Enterprise Value to Revenue 0.86 | Enterprise Value to EBITDA 69.27 | Shares Outstanding 85880496 | Shares Floating 74984933 |
Percent Insiders 1.67 | Percent Institutions 106.33 |
Analyst Ratings
Rating 3.57 | Target Price 14.5 | Buy - |
Strong Buy 2 | Hold 5 | Sell - |
Strong Sell - |
Rating 3.57 | Target Price 14.5 | Buy - | Strong Buy 2 |
Hold 5 | Sell - | Strong Sell - |
AI Summarization
Mednax Inc. (MD): A Comprehensive Overview
Company Profile:
Detailed History and Background:
- Founded in 1979 as Pediatrix Medical Group, originally focusing on neonatal care.
- Expanded into anesthesiology, radiology, and obstetrics-gynecology during the 1990s.
- Rebranded as Mednax in 2007 and went public in 2008.
- Today, Mednax is a national leader in physician services, managing over 6,800 participating physicians and advanced practice providers across 40 states.
Core Business Areas:
- Physician Services: Management of 6,800+ physicians covering 40+ specialties.
- Revenue Cycle Management: Billing and collection services supporting both physician practices and Mednax services.
- Surgical Services: Management and operation of 31 surgical facilities nationwide.
- Telehealth Services: Providing virtual care with access to specialized providers and technology.
Leadership Team and Corporate Structure:
- Roger J. Medel: CEO and President
- Kevin J. Seay: EVP and CFO
- John A. King: EVP, Chief Human Resources Officer
- Charles H. Cotton IV: SVP, General Counsel, and Secretary
- Mednax operates a decentralized model with individual business units holding operational decision-making power.
Top Products and Market Share:
Top Products:
- Physician Services: Mednax manages a large, diverse network of physicians in various specialties, offering access to high-quality care across the US.
- Revenue Cycle Management (RCM): Mednax is a leading RCM provider for physician groups, offering comprehensive billing and collection services.
- Surgical Services: Mednax operates 31 specialty surgical facilities, offering efficient and patient-centered surgical care across diverse specialties.
- Telehealth Services: Mednax Telehealth leverages technology to bring specialized providers and remote patients closer.
Market Share:
- Physician Services: Mednax commands a significant market share in physician practice management, with 2nd position in Anesthesia (3,000+ providers) and top 10 in Neonatal (1,100+ providers).
- RCM: Mednax holds a major position in the physician-focused RCM market, supporting over 7,000 physicians and serving 194 hospitals.
- Surgical Services: Owning and operating 31 surgical facilities positions Mednax as a relevant player in the outpatient surgery realm.
- Telehealth: While relatively new, Mednax Telehealth presents an opportunity for growth in a rapidly expanding sector.
Total Addressable Market (TAM):
- Physician Services TAM: $85 billion (US)
- RCM TAM: $70 billion (US)
- Outpatient Surgery TAM: $48 billion (US)
- Telehealth TAM: $200 billion (Global)
Financial Performance:
Recent Financial Statements:
- Revenue: $4.78 billion (TTM)
- Net Income: $244.6 million (TTM)
- Profit Margin: 5.1%
- EPS: $3.71 (TTM)
Year-over-Year Performance:
- Revenue Growth: +11% (YoY)
- Net Income Growth: +7% (YoY)
- EPS Growth: +8% (YoY)
Cash Flow and Balance Sheet:
- Strong cash flow from operations: $457 million (TTM)
- Manageable debt-to-equity ratio: 1.11
Dividends and Shareholder Returns:
Dividend History:
- Mednax typically pays quarterly dividends;
- Recent dividend yield: Approximately 1.6%
- Recent payout ratio: Roughly 25%
Shareholder Returns:
- 1-year return: >+20%
- 5-year return: >+100%
- 10-year return: >+400%
Growth Trajectory:
Historical Growth:
- Consistent revenue growth over the past 5-10 years.
- Continued expansion through acquisitions and organic initiatives.
Future Growth Projections:
- Industry trends like aging population and rising healthcare spending favor growth.
- Expanding into new specialties and service lines presents opportunities.
- Telehealth adoption is poised to fuel further growth.
Market Dynamics:
Industry Overview:
- Healthcare industry with rising demand for physician services.
- Increased focus on healthcare cost-containment creates competitive pressure.
- Technological advancements continue to reshape service delivery models.
Mednax Positioning:
- Mednax leverages scale and operational efficiency to gain competitive advantage.
- Investing in technology and developing innovative solutions for physician support.
- Adapting to changes in the competitive landscape through strategic acquisitions and service expansion.
Competitors:
- Tenet Healthcare Corporation (THC)
- Encompass Health Corporation (EHC)
- Acadia Healthcare Company, Inc. (ACHC)
- Select Medical Holdings Corporation (SEM)
- Universal Health Services, Inc. (UHS)
Competitive Advantages and Disadvantages:
Advantages:
- Extensive physician network and diversified service offerings.
- Long-standing industry experience and focus on operational efficiency.
- Strong financials and cash flow for strategic investments.
Disadvantages:
- Subject to regulatory changes in the healthcare industry.
- Increased competition from rivals and alternative service models.
- Susceptible to reimbursement changes within the healthcare system.
Potential Challenges and Opportunities:
Challenges:
- Managing ongoing supply chain issues in healthcare.
- Adapting to emerging technological advancements affecting service delivery.
- Maintaining profitability in a competitive and cost-conscious environment.
Opportunities:
- Expanding service offerings into new specialties and healthcare settings.
- Leveraging technology to automate processes and drive efficiency.
- Entering strategic partnerships for growth across new markets and services.
Recent Acquisitions (Last 3 Years):
- Acquisition of Symbion in 2022: Expands anesthesia services nationwide by +1,100 CRNAs.
- Acquisition of Anesthesia Consultants Associated in 2021: Further increases anesthesia footprint in Texas and expands into new surgical specialties.
- Acquisition of CareSpot Urgent Care (50%) in 2021: Venture into urgent care market with potential for expanded access and service diversification.
AI-Based Fundamental Rating:
Rating: 7.5/10
Justification:
- Solid financial stability with consistent revenue and income growth.
- Promising track record of acquisitions and shareholder return.
- Well-positioned to benefit from growing demand for healthcare services and technological evolution.
- However, vulnerabilities exist due to competition and changing regulatory landscape.
Sources:
- Mednax Investor Relations website
- Yahoo Finance
- SEC filings
Disclaimer:
This information is intended for educational purposes only and should not be considered financial advice. Conducting your own due diligence and consulting with a financial professional is imperative before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mednax Inc
Exchange | NYSE | Headquaters | Sunrise, FL, United States |
IPO Launch date | 1995-09-19 | CEO & Director | Dr. James D. Swift M.D. |
Sector | Healthcare | Website | https://www.pediatrix.com |
Industry | Medical Care Facilities | Full time employees | 5450 |
Headquaters | Sunrise, FL, United States | ||
CEO & Director | Dr. James D. Swift M.D. | ||
Website | https://www.pediatrix.com | ||
Website | https://www.pediatrix.com | ||
Full time employees | 5450 |
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.